OrbiMed jumped to the number one spot on this year’s Top 100 biotech venture investors list after more than doubling its deal activity to $5.9 billion in 2025, with the rankings and data compiled and fact-checked by DealForma’s Chris Dokomajilar. Read it here
DealForma is the biopharma deal database providing you comprehensive information and dedicated analyst support to help you be more confident using quality data in your business development research.
Database
Company
Comparisons
Website Design by Once Interactive
